A double-blind trial of baclofen against placebo in the treatment of schizophrenia.
Twenty male chronic schizophrenic patients participated in a double-blond between-patient study of the GABA-like drug baclofen to evaluate the antipsychotic effect of baclofen. No difference was found between the 10 patients who received baclofen and 10 who received placebo with regard to the number of days before a worsening of their psychiatric condition necessitated treatment with chlorpromazine, the total score for psychotic symptoms before and after treatment for 10 weeks, or the total consumption of chlorpromazine. Discontinuation of baclofen did not exacerbate the psychotic symptoms. Baclofen was superior to placebo in the treatment of anxiety, which is of particular interest in view of the recent theories on the mechanism of action of benzodiazepines. The relationship between the gabergic system and the dopaminergic system with regard to the substantia nigra and the corpus striatum is discussed as well as the suggestion based on animal experiments that baclofen has an antipsychotic effect.
D000328:Adult; D000613:Aminobutyrates / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D001418:Baclofen / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*
D000613:Aminobutyrates; D010919:Placebos; D001418:Baclofen; D002746:Chlorpromazine